Obiltoxaximab

Summary

Obiltoxaximab (CHEMBL3544926) is an approved antibody (ATC J06BC04); indicated across 1 condition including anthrax infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: J06BC04
• Indications: 1 condition
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3544926
Name	Obiltoxaximab
Type	Antibody
Max phase	4
ATC	J06BC04

Also known as: Anthim, ETI-204, Obiltoxaximab, OBILTOXAXIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anthrax infection	4	MONDO:0005119	EFO:0000778

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE1	7
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03088111	PHASE4	UNKNOWN	An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis
NCT00138411	PHASE1	COMPLETED	Monoclonal Antibody for Treatment of Inhalation Anthrax
NCT00829582	PHASE1	COMPLETED	Intravenous Dose-Escalation Study With ETI-204 in Adult Volunteers
NCT01453907	PHASE1	COMPLETED	Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers
NCT01929226	PHASE1	COMPLETED	Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers
NCT01932242	PHASE1	COMPLETED	Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers
NCT01932437	PHASE1	COMPLETED	Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers
NCT01952444	PHASE1	COMPLETED	Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).